Global Pipeline Review & Analysis of Hematological Malignancies

Table of Contents

1 EXECUTIVE SUMMARY

2 CANCER HIGHLIGHTS

TABLE OF CONTENTS

• 2.1 LIST OF FIGURES
• 2.2 LIST OF TABLES

3 PLAYERS IN THE FIELD OF HEMATOLOGICAL MALIGNANCIES

4 THE HEMATOLOGICAL CANCER DRUG PIPELINE

• 4.1 DRUG PIPELINE BY LEUKEMIA
• 4.2 DRUG PIPELINE BY LYMPHOMA

5 PROTEIN TARGETS IN HEMATOLOGICAL CANCERS

• 5.1 PURSUED TARGETS IN LEUKEMIA
• 5.2 PURSUED TARGETS IN LYMPHOMA

6 COMPOUNDS

• 6.1 OVERVIEW OF COMPOUNDS
• 6.2 PRESENTATION OF BIOLOGICAL COMPOUNDS USED IN HEMATOLOGICAL CANCERS
• 6.3 PRESENTATION OF CHEMICAL COMPOUNDS USED IN HEMATOLOGICAL CANCERS
• 6.4 PRESENTATION OF NATURAL COMPOUNDS USED IN HEMATOLOGICAL CANCERS
• 6.5 LEUKEMIA BY COMPOUND TYPES
• 6.6 LYMPHOMA BY COMPOUND TYPE

7 TARGETED THERAPIES IN HEMATOLOGICAL CANCERS

• 7.1 TARGETED THERAPIES IN LEUKEMIA
• 7.2 TARGETED THERPIES IN LYMPHOMA

8 TARGETED THERAPY STRATEGIES VERSUS COMPOUND TYPES IN HEMATOLOGICAL CANCERS

• 8.1 TARGETED THERAPY STRATEGIES VERSUS COMPOUND TYPES IN LEUKEMIA
• 8.2 TARGETED THERAPY STRATEGIES VERSUS COMPOUND TYPES IN LYMPHOMA

9 PURSUED SIGNALING PATHWAYS IN HEMATOLOGICAL CANCERS

• 9.1 ALPHA6 BETA4 INTEGRIN SIGNALING PATHWAY
  • 9.1.1 DESCRIPTION OF PATHWAY
  • 9.1.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
• 9.2 ANDROGEN RECEPTOR SIGNALING PATHWAY
  • 9.2.1 DESCRIPTION OF PATHWAY
  • 9.2.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
• 9.3 B CELL RECEPTOR SIGNALING PATHWAY
  • 9.3.1 DESCRIPTION OF PATHWAY
  • 9.3.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
• 9.4 EGFR1 SIGNALING PATHWAY
  • 9.4.1 DESCRIPTION OF PATHWAY
  • 9.4.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
• 9.5 ID SIGNALING PATHWAY
  • 9.5.1 DESCRIPTION OF PATHWAY
  • 9.5.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
• 9.6 IL-1 SIGNALING PATHWAY
  • 9.6.1 DESCRIPTION OF PATHWAY
  • 9.6.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
• 9.7 IL-2 SIGNALING PATHWAY
  • 9.7.1 DESCRIPTION OF PATHWAY
  • 9.7.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
• 9.8 IL-3 SIGNALING PATHWAY
  • 9.8.1 DESCRIPTION OF PATHWAY
  • 9.8.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
• 9.9 IL-4 SIGNALING PATHWAY
  • 9.9.1 DESCRIPTION OF PATHWAY
  • 9.9.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
• 9.10 IL-5 SIGNALING PATHWAY
  • 9.10.1 DESCRIPTION OF PATHWAY
  • 9.10.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
• 9.11 IL-6 SIGNALING PATHWAY
  • 9.11.1 DESCRIPTION OF PATHWAY
  • 9.11.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
• 9.12 IL-7 SIGNALING PATHWAY
  • 9.12.1 DESCRIPTION OF PATHWAY
  • 9.12.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
• 9.13 KIT RECEPTOR SIGNALING PATHWAY
  • 9.13.1 DESCRIPTION OF PATHWAY
  • 9.13.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
• 9.14 NOTCH SIGNALING PATHWAY
  • 9.14.1 DESCRIPTION OF PATHWAY
  • 9.14.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
• 9.15 T CELL RECEPTOR SIGNALING PATHWAY
  • 9.15.1 DESCRIPTION OF PATHWAY
  • 9.15.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
• 9.16 TGF-BETA RECEPTOR SIGNALING PATHWAY
  • 9.16.1 DESCRIPTION OF PATHWAY
  • 9.16.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
• 9.17 TNF-ALPHA SIGNALING PATHWAY
  • 9.17.1 DESCRIPTION OF PATHWAY
  • 9.17.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
• 9.18 WNT SIGNALING PATHWAY
  • 9.18.1 DESCRIPTION OF PATHWAY
  • 9.18.2 HEMATOLOGICAL CANCER DRUG CANDIDATES

10 BRIEF DRUG DESCRIPTION

11 DISCLAIMER

• 11.1 LIABILITY
• 11.2 COMPLETENESS

List of Figures

• Figure 1: The Hematological Cancer Developmental Pipeline
• Figure 2: The Leukemia Developmental Pipeline
• Figure 3: The Lymphoma Developmental Pipeline
• Figure 4: Leukemia Drug Candidates by Developmental Stage, Sub-indication Vrs Primary Target Localization
• Figure 5: Leukemia Drug Candidates by Developmental Stage, Sub-indication Vrs Biological Process of Target
• Figure 6: Leukemia Drug Candidates by Developmental Stage and Sub-indication Vrs Molecular Class of Target
• Figure 7: Lymphoma Drug Candidates by Developmental Stage, Sub-indication Vrs Primary Target Localization
• Figure 8: Lymphoma Drug Candidates by Developmental Stage, Sub-indication Vrs Biological Process of Target
• Figure 9: Lymphoma Drug Candidates by Developmental Stage, Sub-indication Vrs Molecular Class of Target
• Figure 10: Distribution of Compound Types in the Hematological Malignancies Pipeline
• Figure 11: Leukemia Drug Candidates Presented by Developmental Stage and Sub-Indication Vrs Compound Type
• Figure 12: Lymphoma Drug Candidates Presented by Developmental Stage and Sub-Indication Vrs Compound Type
• Figure 13: Leukemia Drug Candidates by Developmental Stage and Sub-indication Vrs Targeted Therapy Type
• Figure 14: Lymphoma Drug Candidates by Developmental Stage and Sub-indication Vrs Targeted Therapy Type
• Figure 15: Angiogenesis - Developmental Stages of Sub indications of Leukemia Versus Compound Type
• Figure 16: Apoptosis - Developmental Stages of Sub indications of Leukemia Versus Compound Type
• Figure 17: Protein Kinase Inhibitors - Developmental Stages of Sub indications of Leukemia Versus Compound Type
• Figure 18: Vaccines - Developmental Stages of Sub indications of Leukemia Versus Compound Type
• Figure 19: Angiogenesis - Developmental Stages of Sub indications of Lymphoma Versus Compound Type
• Figure 20: Apoptosis - Developmental Stages of Sub indications of Lymphoma Versus Compound Type
• Figure 21: Protein Kinase Inhibitor - Developmental Stages of Sub indications of Lymphoma Versus Compound Type
• Figure 22: Vaccines - Developmental Stages of Sub indications of Lymphoma Versus Compound Type
• Figure 23: Drug Candidates Involving the Alpha6 Beta4 Integrin Signaling Pathway for the Treatment of Hematological Cancers
• Figure 24: Drug Candidates Involving the Androgen Receptor Signaling Pathway for the Treatment of Hematological Cancers
• Figure 25: Drug Candidates Involving the B Cell Receptor Signaling Pathway for the Treatment of Hematological Cancers
• Figure 26: Drug Candidates Involving the EGFR1 Signaling Pathway for the Treatment of Hematological Cancers
• Figure 27: Drug Candidates Involving the ID Signaling Pathway for the Treatment of Hematological Cancers
• Figure 28: Drug Candidates Involving the IL-1 Signaling Pathway for the Treatment of Hematological Cancers
• Figure 29: Drug Candidates Involving the IL-2 Signaling Pathway for the Treatment of Hematological Cancers
• Figure 30: Drug Candidates Involving the IL-3 Signaling Pathway for the Treatment of Hematological Cancers
• Figure 31: Drug Candidates Involving the IL-4 Signaling Pathway for the Treatment of Hematological Cancers
• Figure 32: Drug Candidates Involving the IL-5 Signaling Pathway for the Treatment of Hematological Cancers
• Figure 33: Drug Candidates Involving the IL-6 Signaling Pathway for the Treatment of Hematological Cancers
• Figure 34 Drug Candidates Involving the IL-7 Signaling Pathway for the Treatment of Hematological Cancers
• Figure 35: Drug Candidates Involving the Kit Receptor Signaling Pathway for the Treatment of Hematological Cancers
• Figure 36: Drug Candidates Involving the Notch Signaling Pathway for the Treatment of Hematological Cancers
• Figure 37: Drug Candidates Involving the T Cell Receptor Signaling Pathway for the Treatment of Hematological Cancers
• Figure 38: Drug Candidates Involving the TGF-beta Receptor Signaling Pathway for the Treatment of Hematological Cancers
• Figure 39: Drug Candidates Involving the TNF-alpha Signaling Pathway for the Treatment of Hematological Cancers
• Figure 40: Drug Candidates Involving the Wnt Signaling Pathway for the Treatment of Hematological Cancers

List of Tables

• Table 1: List of Active Players in the Field of Hematological Malignancies
• Table 2: The Leukemia Developmental Pipeline
• Table 3: The Lymphoma Developmental Pipeline
• Table 4: List of Pursued Protein Targets in Hematological Cancers
• Table 5: Hematological Cancer Targets by Investigator and Drug
• Table 6: Pursued Targets by Sub-indications of Leukemia
• Table 7: Pursued Targets by Sub-indications of Lymphoma
• Table 8: Drug Candidates with Its Corresponding Compound Types Listed by Investigator
• Table 9: List of Biological Compounds
• Table 10: List of Chemical Compounds
• Table 11: List of Natural Compounds
• Table 12: Developmental Stage and Sub Indication by Compounds Type in Leukemia
• Table 13: Developmental Stage and Sub indication bt Compound Types in Lymphoma
• Table 14: List of Targeted Therapies in Leukemia
• Table 15: List of Targeted Therapies in Lymphoma
• Table 16: Targeted Therapy Strategies Versus Compound Type in Leukemia
• Table 17: Targeted Therapy Strategies Versus Compound Types in Lymphoma
• Table 18: Targets Linking Drugs to the Alpha6 Beta4 Integrin Signaling Pathway
• Table 19: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the Alpha6 Beta4 Integrin Signaling Pathway
• Table 20: Targets Linking Drugs to the Androgen Receptor Signaling Pathway
• Table 21: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the Androgen Receptor Signaling Pathway
• Table 22: Targets Linking Drugs to the B Cell Receptor Signaling Pathway
• Table 23: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the B Cell Receptor Signaling Pathway
• Table 24: Targets Linking Drugs to the EGFR1 Signaling Pathway
• Table 25: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the EGFR1 Signaling Pathway
• Table 26: Targets Linking Drugs to the ID Signaling Pathway
• Table 27: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the ID Signaling Pathway
• Table 28: Targets Linking Drugs to the IL-1 Signaling Pathway
• Table 29: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the IL-1 Signaling Pathway
• Table 30: Targets Linking Drugs to the IL-2 Signaling Pathway
• Table 31: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the IL-2 Signaling Pathway
• Table 32: Targets Linking Drugs to the IL-3 Signaling Pathway
• Table 33: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the IL-3 Signaling Pathway
• Table 34: Targets Linking Drugs to the IL-4 Signaling Pathway
• Table 35: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the IL-4 Signaling Pathway
• Table 36: Targets Linking Drugs to the IL-5 Signaling Pathway
• Table 37: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the IL-5 Signaling Pathway
• Table 38: Targets Linking Drugs to the IL-6 Signaling Pathway
• Table 39: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the IL-6 Signaling Pathway
• Table 40: Targets Linking Drugs to the IL-7 Signaling Pathway
• Table 41: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the IL-7 Signaling Pathway
• Table 42: Targets Linking Drugs to the Kit Receptor Signaling Pathway
• Table 43: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the Kit Receptor Signaling Pathway
• Table 44: Targets Linking Drugs to theNotch Signaling Pathway
• Table 45: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the Notch Signaling Pathway
• Table 46: Targets Linking Drugs to the T Cell Receptor Signaling Pathway
• Table 47: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the T Cell Receptor Signaling Pathway
• Table 48: Targets Linking Drugs to the TGF-beta Signaling Pathway
• Table 49: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the TGF-beta Receptor Signaling Pathway
• Table 50: Targets Linking Drugs to the TNF-alpha Signaling Pathway
• Table 51: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the TNF-alpha Signaling Pathway
• Table 52: Targets Linking Drugs to the Wnt Signaling Pathway
• Table 53: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the Wnt Signaling Pathway